Picture of virus

Open Access research that helps to deliver "better medicines"...

Strathprints makes available scholarly Open Access content by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), a major research centre in Scotland and amongst the UK's top schools of pharmacy.

Research at SIPBS includes the "New medicines", "Better medicines" and "Better use of medicines" research groups. Together their research explores multidisciplinary approaches to improve understanding of fundamental bioscience and identify novel therapeutic targets with the aim of developing therapeutic interventions, investigation of the development and manufacture of drug substances and products, and harnessing Scotland's rich health informatics datasets to inform stratified medicine approaches and investigate the impact of public health interventions.

Explore Open Access research by SIPBS. Or explore all of Strathclyde's Open Access research...

Identification of the benzodiazepines as a new class of antileishmanial agent

Clark, Rachael L. and Carter, Katharine C. and Mullen, Alexander B. and Coxon, Geoffrey D. and Owusu-Dapaah, George and McFarlane, Emma and Dao Duong Thi, M. and Grant, M.H. and Tettey, J.N.A. and Mackay, Simon P. (2007) Identification of the benzodiazepines as a new class of antileishmanial agent. Bioorganic and Medicinal Chemistry Letters, 17 (3). pp. 624-627. ISSN 0960-894X

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

The continual increase in drug resistance; the lack of new chemotherapeutic agents; the toxicity of existing agents and the increasing morbidity with HIV co-infection mean the search for new antileishmanial agents has never been more urgent. We have identified the benzodiazepines as a structural class for antileishmanial hit optimisation, and demonstrated that their in vitro activity is comparable with the clinically used drug, sodium stibogluconate, and that the compounds are not toxic to macrophages.